APG279-101 Enrolling

Atopic Dermatitis Study (82 Weeks)


Treatment: Injection Age: 18 Years and above


Who Can Participate?
Adults aged 18 years or above

Inclusion Criteria
• Have a diagnosis of AD that has been present for ≥ 1 year
• Have a diagnosis of AD affecting ≥ 10% of body surface area (BSA)
• Have a history of inadequate response to treatment with topical medications, or medical determination that topical therapies are
inadvisable
• Have applied a stable dose of non-medicated over-the-counter emollient/moisturizer of one’s choice on their skin (except those
containing urea, camphor, or menthol) for ≥ 14 days and agrees to continue using the same moisturizer at the same frequency (ideally
once or twice daily) throughout the study

Participant Information
• Participate and receive study treatment at no cost
• Regular visits with study doctors who specialise in treating atopic dermatitis (24 visits)
• Will receive an investigative subcutaneous treatment (study drug)
• Reimbursement for study-related expenses may be provided

How Long Will The Study Last?
• 82 weeks


Participating Locations

COUNTRY
country-icon
Australia

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: June 23, 2025

Official Title

A Phase 1b, Open-label, Randomized, Multicenter, Active Comparator Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Combination of APG777 + APG990 in Adults With Moderate-to-Severe Atopic Dermatitis

ClinicalTrials.gov ID

NCT07027527

Sponsor

Apogee Therapeutics, Inc.

Study Description

  • Brief Summary:

    The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. The duration of the study will be approximately 82 weeks for each participant and will consist of a Screening Period (up to 6 weeks), Treatment Period (Baseline-Week 24), and Follow-up Period (Week 28-Week 76).

  • Condition or Disease:

    Atopic Dermatitis

  • Intervention/Treatment:

    Drug: APG777,Drug: APG990 Drug: Dupilumab
  • Phase:

    PHASE1

  • Ages Eligible for Study:

    18 Years and older (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL

Inclusion Criteria
• Have a diagnosis of AD that has been present for ≥ 1 year
• Have a diagnosis of AD affecting ≥ 10% of body surface area (BSA)
• Have a history of inadequate response to treatment with topical medications, or medical determination that topical therapies are
inadvisable
• Have applied a stable dose of non-medicated over-the-counter emollient/moisturizer of one’s choice on their skin (except those
containing urea, camphor, or menthol) for ≥ 14 days and agrees to continue using the same moisturizer at the same frequency (ideally
once or twice daily) throughout the study


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

ECZEMA - ATOPIC DERMATITIS

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content